| [1] |
邵志敏,沈镇宙,徐兵河. 乳腺肿瘤学[M]. 上海: 复旦大学出版社, 2013: 10.
|
| [2] |
Gu G,Dustin D,Fuqua SA. Targeted therapy for breast cancer and molecular mechanisms of resistance to treatment[J]. Curr Opin Pharmacol, 2016, 31: 97-103.
|
| [3] |
Hsu JL,Hung MC. The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer[J]. Cancer Metastasis Rev, 2016, 35(4): 575-588.
|
| [4] |
连婧,马海霞,白玮, 等. 乳腺癌的分子分型及其临床病理特征[J/CD]. 中华乳腺病杂志(电子版), 2016, 10(3): 183-184.
|
| [5] |
National Comprehensive Cancer Network. National Comprehensive Cancer Network guidelines for breast cancer[EB/OL]．[2018-01-05].
URL
|
| [6] |
Ma CX,Reinert T,Chmielewska I, et al. Mechanisms of aromatase inhibitor resistance[J]. Nat Rev Cancer, 2015, 15(5): 261-275.
|
| [7] |
Pritchard KI. Endocrine therapy: is the first generation of targeted drugs the last? [J]. J Intern Med, 2013, 274(2): 144-152.
|
| [8] |
Farzaneh S,Zarghi A. Estrogen receptor ligands: a review (2013-2015) [J]. Sci Pharm, 2016, 84(3): 409-427.
|
| [9] |
Toy W,Weir H,Razavi P, et al. Activating ESR1 mutations differentially affect the efficacy of ER antagonists[J]. Cancer Discov, 2016, 7(3): 277-287.
|
| [10] |
Pejerrey SM,Dustin D,Kim JA, et al. The impact of ESR1 mutations on the treatment of metastatic breast cancer[EB/OL]. [2018-05-07].
URL
|
| [11] |
Toy W,Shen Y,Won H, et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer[J]. Nat Genet, 2013, 45(12): 1439-1445.
|
| [12] |
Robinson DR,Wu YM,Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer[J]. Nat Genet, 2013, 45(12): 1446-1451.
|
| [13] |
Li S,Shen D,Shao J, et al. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts[J]. Cell Rep, 2013, 4(6): 1116-1130.
|
| [14] |
Fanning SW,Mayne CG,Dharmarajan V, et al. Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation[J]. Elife, 2016, 5: e12792.
|
| [15] |
Jeselsohn R,Yelensky R,Buchwalter G, et al. Emergence of constitutively active estrogen receptor-alpha mutations in pretreated advanced estrogen receptor-positive breast cancer[J]. Clin Cancer Res, 2014, 20(7): 1757-1767.
|
| [16] |
Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours[J]. Nature, 2012, 490(7418): 61-70.
|
| [17] |
Bartels S,Christgen M,Luft A, et al. Estrogen receptor (ESR1) mutation in bone metastases from breast cancer[J]. Mod Pathol, 2018, 31(1): 56-61.
|
| [18] |
Cristofanilli M,Turner NC,Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial[J]. Lancet Oncol, 2016, 17(4): 425-439.
|
| [19] |
Fribbens C,O’Leary B,Kilburn L, et al. Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer[J]. J Clin Oncol, 2016, 34(25): 2961-2968.
|
| [20] |
Fei M,Yan Z,Quchang O, et al. Mutation signature of patients with ER＋ metastatic breast cancer who received endocrine therapy[EB/OL]．[2018-05-20].
URL
|
| [21] |
Wang P,Bahreini A,Gyanchandani R, et al. Sensitive detection of mono- and polyclonal esr1 mutations in primary tumors, metastatic lesions, and cell-free DNA of breast cancer patients[J]. Clin Cancer Res, 2016, 22(5): 1130-1137.
|
| [22] |
Johnston SR,Kilburn LS,Ellis P, et al. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): A composite, multicentre, phase 3 randomised trial[J]. Lancet Oncol, 2013, 14(10): 989-998.
|
| [23] |
Chandarlapaty S,Chen D,He W, et al. Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer: a secondary analysis of the BOLERO-2 Clinical Trial[J]. JAMA Oncol, 2016, 2(10): 1310-1315.
|
| [24] |
Hartmaier RJ,Trabucco SE,Priedigkeit N, et al. Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer[J]. Ann Oncol, 2018, 29(4): 872-880.
|
| [25] |
Tokunaga E,Hisamatsu Y,Tanaka K, et al. Molecular mechanisms regulating the hormone sensitivity of breast cancer[J]. Cancer Sci, 2014, 105(11): 1377-1383.
|
| [26] |
Frogne T,Benjaminsen RV,Sonne-Hansen K, et al. Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant[J]. Breast Cancer Res Treat, 2009, 114(2): 263-275.
|
| [27] |
Formisano L,Young CD,Bhola N, et al. FGFR1 is associated with resistance to interaction with estrogen receptor (ER) α endocrine therapy in ER＋/FGFR1-amplified breast cancer[EB/OL]．[2017-01-05].
URL
|
| [28] |
Matà R,Palladino C,Nicolosi ML, et al. IGF-I induces upregulation of DDR1 collagen receptor in breast cancer cells by suppressing MIR-199a-5p through the PI3K/AKT pathway[J]. Oncotarget, 2016, 7(7): 7683-7700.
|
| [29] |
García-Becerra R,Santos N,Díaz L, et al. Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance[J]. Int J Mol Sci, 2012, 14(1): 108-145.
|
| [30] |
Zhao M,Ramaswamy B. Mechanisms and therapeutic advances in the management of endocrine-resistant breast cancer[J]. World J Clin Oncol, 2014, 5(3): 248-262.
|
| [31] |
Nardone A,De Angelis C,Trivedi MV, et al. The changing role of ER in endocrine resistance[J]. Breast, 2015, 24(2): S60-66.
|
| [32] |
Lau KM,To KF. Importance of estrogenic signaling and its mediated receptors in prostate cancer[J]. Int J Mol Sci, 2016, 17(9): 1434.
|
| [33] |
Garee JP,Chien CD,Li JV, et al. Regulation of HER2 oncogene transcription by a multifunctional coactivator/corepressor complex[J]. Mol Endocrinol, 2014, 28(6): 846-859.
|
| [34] |
Rondón-Lagos M,Villegas VE,Rangel N, et al. Tamoxifen resistance: emerging molecular targets[J]. Int J Mol Sci, 2016, 17(8): 1357.
|
| [35] |
Kavarthapu R,Dufau ML. Role of EGF/ERBB1 in the transcriptional regulation of the prolactin receptor independent of estrogen and prolactin in breast cancer cells[J]. Oncotarget, 2016, 7(40): 65 602-65 613.
|
| [36] |
Arpino G,Wiechmann L,Osborne CK. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance[J]. Endocr Rev, 2008, 29(2): 217-233.
|
| [37] |
Lousberg L,Collignon J,Jerusalem G. Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategies[J]. Ther Adv Med Oncol, 2016, 8(6): 429-449.
|
| [38] |
Shou J,Massarweh S,Osborne CK, et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer[J]. J Natl Cancer Inst, 2004, 96(12): 926-935.
|
| [39] |
Milani A,Geuna E,Mittica G, et al. Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions[J]. World J Clin Oncol, 2014, 5(5): 990-1001.
|
| [40] |
Lonard DM,O’Malley BW. Molecular pathways: targeting steroid receptor coactivators in cancer[J]. Clin Cancer Res, 2016, 22(22): 5403-5407.
|
| [41] |
Lee A,Guler B,Sun X, et al. Oestrogen receptor is a critical component required for insulin-like growth factor (IGF)-mediated signalling and growth in MCF-7 cells[J]. Eur J Cancer, 2000, 36(Suppl 4): 109-110.
|
| [42] |
Azim H,Piccart M. Simultaneous targeting of estrogen receptor and HER2 in breast cancer[J]. Expert Rev Anticancer Ther, 2010, 10(8): 1255-1263.
|
| [43] |
Cardoso F,Costa A,Norton L, et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) [J]. Ann Oncol, 2014, 25(10): 1871-1888.
|
| [44] |
Ro J,Pippen J,Pivot X, et al. Safety of first-line letrozole compared with lapatinib plus letrozole in patients with postmenopausal hormone receptor positive metastatic breast cancer: EGF30008 study[EB/OL]．[2018-01-05].
URL
|
| [45] |
Bose R,Kavuri SM,Searleman AC, et al. Activating HER2 mutations in HER2 gene amplif cation negative breast cancer[J]. Cancer Discov, 2013, 3(2): 1-14.
|
| [46] |
Prové A,Dirix L. Neratinib for the treatment of breast cancer[J]. Expert Opin Pharmacother, 2016, 17(16): 2243-2248.
|
| [47] |
Deluche E,Onesti E,Andre F. Precision medicine for metastatic breast cancer[J]. Am Soc Clin Oncol Educ Book, 2015, 35: e2-7.
|
| [48] |
Osborne CK,Neven P,Dirix LY, et al. Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase Ⅱ study[J]. Clin Cancer Res, 2011, 17(5): 1147-1159.
|
| [49] |
Cristofanilli M,Valero V,Mangalik A, et al. Phase Ⅱ, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer[J]. Clin Cancer Res, 2010, 16(6): 1904-1914.
|
| [50] |
Guerrero-Zotano A,Mayer IA,Arteaga CL.PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment[J]. Cancer Metastasis Rev, 2016, 35(4): 1-10.
|
| [51] |
Thorpe LM,Yuzugullu H,Zhao JJ. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting[J]. Nat Rev Cancer, 2015, 15(1): 7-24.
|
| [52] |
Arthur LM,Turnbull AK,Renshaw L, et al. Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer[J]. Breast Cancer Res Treat, 2014, 147(1): 211-219.
|
| [53] |
Ciriello G,Gatza ML,Beck AH, et al. Comprehensive molecular portraits of invasive lobular breast cancer [J]. Cell, 2015, 163(2): 506-519.
|
| [54] |
Lauring J,Park BH,Wolff AC. The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer[J]. J Natl Compr Canc Netw, 2013, 11(6): 670-678.
|
| [55] |
Bosch A,Li Z,Bergamaschi A, et al. PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer[J]. Sci Transl Med, 2015, 7(283): 283ra51.
|
| [56] |
Moynahan ME,Chen D,He W, et al. Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR＋, HER2- advanced breast cancer: results from BOLERO-2[J]. Br J Cancer, 2017, 116(6): 726-730.
|
| [57] |
Schwartz S,Wongvipat J,Trigwell CB, et al. Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ[J]. Cancer Cell, 2015, 27(1): 109-122.
|
| [58] |
Baselga J,Im SA,Iwata H, et al. PIK3CA status in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HR＋/HER2- advanced breast cancer (BC): first results from the randomized, phase Ⅲ BELLE-2 trial[J]. Cancer Res, 2016, 76(4 Suppl): S6.
|
| [59] |
Dickler MN,Saura C,Richards DA, et al. A phase Ⅱ study of the PI3K inhibitor taselisib (GDC-0032) combined with fulvestrant (F) in patients (pts) with HER2-negative (HER2-), hormone receptor-positive (HR＋) advanced breast cancer (BC) [J]. J Clin Oncol, 2016, 34(15): 520.
|
| [60] |
Baselga J,Dent SF,Cortés J, et al. Phase Ⅲ study of taselisib (GDC-0032) ＋ fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER[EB/OL]．[2018-01-05]．
URL
|
| [61] |
Fritsch C,Huang A,Chatenay-Rivauday C, et al. Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials[J]. Mol Cancer Ther, 2014, 13(5): 1117-1129.
|
| [62] |
Rugo HS,Bianchi GV,Chia SK, et al. BYLieve: a phase Ⅱ study of alpelisib (ALP) with fulvestrant (FUL) or letrozole (LET) for treatment of PIK3CA mutant, hormone receptor-positive (HR＋), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (aBC) progressing on/after cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy[EB/OL]．[2018-01-05].
URL
|
| [63] |
Tomiguchi M,Yamamoto Y,Yamamoto-Ibusuki M, et al. Fibroblast growth factor receptor-1 protein expression is associated with prognosis in estrogen receptor-positive/human epidermal growth factor receptor-2-negative primary breast cancer[J]. Cancer Sci, 2016, 107(4): 491-498.
|
| [64] |
André F,Bachelot T,Campone M, et al. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer[J]. Clin Cancer Res, 2013, 19(13): 3693-3702.
|
| [65] |
Robertson JF,Ferrero JM,Bourgeois H, et al. Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomized, controlled, double-blind, phase 2 trial[J]. Lancet Oncol, 2013, 14(3): 228-235.
|
| [66] |
Murphy CG,Dickler MN. The role of CDK4/6 inhibition in breast cancer[J]. Oncologist, 2015, 20(5): 483-490.
|
| [67] |
Murphy CG,Dickler MN. Endocrine resistance in hormone-responsive breast cancer: mechanisms and therapeutic strategies[J]. Endocr Relat Cancer, 2016, 23(8): R337-R352.
|
| [68] |
Vélez-Cruz R,Manickavinayaham S,Biswas AK, et al. RB localizes to DNA double-strand breaks and promotes DNA end resection and homologous recombination through the recruitment of BRG1[J]. Genes Dev, 2016, 30(22): 2500-2512.
|
| [69] |
Finn RS,Crown JP,Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study[J]. Lancet Oncol, 2015, 16(1): 25-35.
|
| [70] |
Otto T,Sicinski P. Cell cycle proteins as promising targets in cancer therapy[J]. Nat Rev Cancer, 2017, 27, 17(2): 93-115.
|
| [71] |
Ellis MJ,Llombart-Cussac A,Feltl D, et al. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: overall survival analysis from the phase Ⅱ first study[J]. J Clin Oncol, 2015, 33(32): 3781-3787.
|
| [72] |
Angus L,Beije N,Jager A, et al. ESR1 mutations: moving towards guiding treatment decision-making in metastatic breast cancer patients[J]. Cancer Treat Rev, 2017, 52: 33-40.
|
| [73] |
Selli C,Dixon JM,Sims AH. Accurate prediction of response to endocrine therapy in breast cancer patients: current and future biomarkers[J]. Breast Cancer Res, 2016, 18(1): 118.
|